Login / Signup

Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations.

Arjun GuptaMichelle TregearMakala B PaceRachel Isaksson Vogel
Published in: JCO oncology practice (2024)
Time and other considerations when evaluating a switch to newer drug formulations (eg, subQ vs IV).
Keyphrases
  • papillary thyroid
  • adverse drug
  • high dose
  • squamous cell
  • squamous cell carcinoma
  • low dose
  • childhood cancer
  • electronic health record